The Ferret in Nausea and Vomiting Research: Lessons in Translation of Basic Science to the Clinic

Biology and Diseases of the Ferret: Third Edition

Volumn , Issue , 2014, Pages 735-778

  du Sert, Nathalie Percie ^a   Andrews, Paul L R ^b  

^a National Centre for the Replacement   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Emesis research; Ferret; Nausea research; Pharmaceutical companies; Vomiting research

Indexed keywords

EID: 84903691672     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118782699.ch31     Document Type: Chapter

References (274)

1. Bernard C (1949) An introduction to the study of experimental medicine, HC Green, trans. New York: Henry Schuman. (Original work published in 1865).
2. Blackburn-Munro G (2004) Pain-like behaviors in animals - how human are they? Trends Pharmacol Sci 25: 299-305.
3. Geyer MA, Markou A (2002) The role of preclinical models in the development of psychotropic drugs. In: Davies KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: the fifth generation of progress: an official publication of the American College of Neuropsychopharmacology. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 445-455.
4. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97: 3090-3098.
5. Stern RM, Andrews PLR, Koch KL (2011) Nausea: mechanisms and management. New York: Oxford University Press, Inc.
6. Andrews PLR, Sanger GJ (2013) Nausea and the quest for the perfect anti-emetic. Eur. J. Pharmacol 722: 108-121.
7. Florczyk AP, Schurig JE, Lenaz L, Bradner WT (1981) The ferret: a new animal model of cis-platinum induced emesis. Proc Am Assoc Cancer Res 22: 228.
8. Borison HL, Wang SC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5: 193-230.
9. Ueno S, Matsuki N, Saito H (1987) Suncus murinus: a new experimental model in emesis research. Life Sci 41: 513-518.
10. Ueno S, Matsuki N, Saito H (1988) Suncus murinus as a new experimental model for motion sickness. Life Sci 43: 413-420.
11. Darmani NA (1998) Serotonin 5-HT3 receptor antagonists prevent cisplatin-induced emesis in Cryptotis parva: a new experimental model of emesis. J Neural Transm 105: 1143-1154.
12. Magendie F (1813) Memoire sure le vomissement. Paris, p. 48.
13. Wepfer JJ (1679) Historia Cicutae Aquatica. Basil.
14. Magnus R (1903) Ergebn. D. Physiologie, II Jahrg. Abt. II (Asher-Spiro). 641.
15. Hatcher RA, Weiss S (1923) Studies on vomiting. J Pharmacol Exp Ther. 22: 139-193.
16. Daunton NG (1990) Animal models in motion sickness research. In: Crampton GH (ed), Motion and space sickness. Boca Raton, FL: CRC Press, pp. 87-104.
17. Brizzee KR (1956) Effect of localized brain stem lesions and supradiaphragmatic vagotomy on x-irradiation emesis in the monkey. Am J Physiol 187: 567-570.
18. Court Brown WM (1953) Symptomatic disturbance after single therapeutic dose of x rays; its relationship to the general radiation syndrome. Br Med J 1: 802-805.
19. Costall B, Domeney AM, Naylor RJ (1986) A model of emesis in the common marmoset. Br J Pharmacol 88: 375P.
20. Grelot L, Le Stunff H, Milano S, Blower PR, Romain D (1996) Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet. J Pharmacol Exp Ther 279: 255-261.
21. Lang IM, Sarna SK, Condon RE (1986) Gastrointestinal motor correlates of vomiting in the dog: quantification and characterization as an independent phenomenon. Gastroenterology 90: 40-47.
22. Lang IM, Marvig J, Sarna SK, Condon RE (1986) Gastrointestinal myoelectric correlates of vomiting in the dog. Am J Physiol 251: G830-G838.
23. Rosenberg B, Vancamp L, Trosko JE, Mansour VH (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222: 385-386.
24. Christie DA, Tansey EM, eds. (2007) The discovery, use and impact of platinum salts as chemotherapy agents for cancer. London: Wellcome Witnesses to Twentieth Century Medicine.
25. Harris AL, Cantwell BMJ (1986) Mechanisms and treatment of cytotoxic-induced nausea and vomiting. In: Davis CJ, Lake-Bakaar GV, Grahame-Smith DG, eds. Nausea and vomiting: mechanisms and treatment. Berlin: Springer-Verlag, pp. 78-93.
26. Schurig JE, Florczyk AP, Bradner WT (1984) Evaluation of platinum complexes for emetic potential. In: Hacker MP, Douple EB, Karkoff IH, eds. Platinum coordination complexes in cancer chemotherapy. Boston, MA: Martinus Nijhoff Publishing, pp. 187-209.
27. Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, Braun DW, Jr., Bordin LA, Braun TJ, Young CW (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305: 905-909.
28. Sanger GJ, King FD (1988) From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists. Drug Des Deliv 3: 273-295.
29. Miner WD, Sanger GJ (1986) Inhibition of cisplatininduced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88: 497-499.
30. Costall B, Domeney AM, Naylor RJ, Tattersall FD (1986) 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25: 959-961.
31. Florczyk AP, Schurig JE, Bradner WT (1982) Cisplatininduced emesis in the ferret: a new animal model. Cancer Treat Rep 66: 187-189.
32. Andrews PLR, Rapeport WG, Sanger GJ (1988) Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 9: 334-341.
33. Andrews PLR, Davis CJ, Hawthorn J (1986) Abdominal vagotomy modifies the emetic response to radiation in the ferret. J Physiol 378: 16P.
34. Andrews PL, Hawthorn J (1987) Evidence for an extra-abdominal site of action for the 5-HT3 receptor antagonist BRL24924 in the inhibition of radiationevoked emesis in the ferret. Neuropharmacology 26: 1367-1370.
35. King GL (1988) Characterization of radiation-induced emesis in the ferret. Radiat Res 114: 599-612.
36. King GL, Rabin BM, Weatherspoon JK (1999) 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation. Aviat Space Environ Med 70: 485-492.
37. Soref CM, Hacker TA, Fahl, WE (2012) A new orally active, aninothiol radioprotector-free of nausea and hypotension side effects at its highest radiprotective doses. Int J Radiat Oncol Biphys 82: e701-707.
38. Andrews PLR, Davis CJ, Maskell L, Grahame-Smith DG (1986) Apomorphine-induced vomiting in the ferret: anomalies of response to dose and route of administration. Br J Pharmacol 89: 860P.
39. Wynn RL, Essien E, Thut PD (1993) The effects of different antiemetic agents on morphine-induced emesis in ferrets. Eur J Pharmacol 241: 47-54.
40. Thompson PI, Bingham S, Andrews PLR, Patel N, Joel SP, Slevin ML (1992) Morphine 6-glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret. Br J Pharmacol 106: 3-8.
41. Andrews PLR, Davis CJ, Bingham S, Davidson HI, Hawthorn J, Maskell L (1990) The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 68: 325-345.
42. Howell RE, Muehsam WT, Kinnier WJ (1990) Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci 46: 563-568.
43. Kwak HJ, Nam JY, Song JS, No Z, Yang SD, Cheon HG (2012) Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumin-induced asthma murine model. Eur J Pharmacol 685: 141-148.
44. Hawthorn J, Ostler KJ, Andrews PLR (1988) The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q J Exp Physiol 73: 7-21.
45. Costall B, Domeney AM, Naylor RJ, Tattersall FD (1987) Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs. Neuropharmacology 26: 1321-1326.
46. Stables R, Andrews PLR, Bailey HE, Costall B, Gunning SJ, Hawthorn J, Naylor RJ, Tyers MB (1987) Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev 14: 333-336.
47. Miner WD, Sanger GJ, Turner DH (1987) Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer 56: 159-162.
48. Schurig JE, Florczyk AP, Rose WC, Bradner WT (1982) Antiemetic activity of butorphanol against cisplatininduced emesis in ferrets and dogs. Cancer Treat Rep 66: 1831-1835.
49. Andrews PLR, Bingham S, Davis CJ (1985) Retching evoked by stimulation of abdominal vagal afferent in the anaesthetized ferret. J Physiol 358: 103P.
50. Davis CJ (1988) PhD thesis: Neuropharmacological investigations into the mechanisms of emesis caused by cytotoxic drugs and radiation. Oxford University.
51. Zunini GS, Roth SH, Lucier GE (1990) The inhibitory effect of halothane on the emetic response in the ferret. Can J Physiol Pharmacol 68: 374-378.
52. Minami M, Tamakai H, Ogawa T, Endo T, Hamaue N, Hirafuji M, Yoshioka M, Blower PR (1995) Chemical modulation of 5-HT3 and 5-HT4 receptors affects the release of 5-hydroxytryptamine from the ferret and rat intestine. Res Commun Mol Pathol Pharmacol 89: 131-142.
53. Rudd JA, Chan SW, Ngan MP, Schirner M, Turski L, Wai MK (1998) The anti-emetic potential of ZK 200.775 in the ferret and Suncus murinus: role of the AMPA receptor. Naunyn Schmiedebergs Arch Pharmacol 358(Suppl. 1): 40.40.
54. Rudd JA, Cheng CH, Naylor RJ (1998) Serotoninindependent model of cisplatin-induced emesis in the ferret. Jpn J Pharmacol 78: 253-260.
55. Davis CJ, Lake-Bakaar GV, Grahame-Smith DG (1986) Nausea and vomiting: mechanisms and treatment. Berlin: Springer-Verlag.
56. Davison JS, Harding RK, eds. (1990) Symposium. Nausea and vomiting: a multidisciplinary perspective. Ottawa, Ontario, November 12-13, 1988. Can J Physiol Pharmacol 68: 217-345.
57. Bianchi AL, Grelot L, Miller AD, King GL (1992) Mechanisms and control of emesis. Marseille: John Libbey Eurotext.
58. Reynolds J, Andrews PLR, Davis CJ (1995) Serotonin and the scientific basis of anti-emetic therapy. Oxford: Oxford Clinical Communications.
59. Tattersall FD, Rycroft W, Hill RG, Hargreaves RJ (1994) Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994. Neuropharmacology 33: 259-260.
60. Costall B, Domeney AM, Naylor RJ, Owera-Atepo JB, Rudd JA, Tattersall FD (1990) Fluphenazine, ICS 205-930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret. Neuropharmacology 29: 453-462.
61. Mackay TW, Andrews PL (1983) A comparative study of the vagal innervation of the stomach in man and the ferret. J Anat 136: 449-481.
62. Andrews PL, Fussey IV, Scratcherd T (1980) The spontaneous discharge in abdominal vagal efferents in the dog and ferret. Pflugers Arch 387: 55-60.
63. Wood KL (1988) Aspects of the central control of gastric motility in the ferret and rat. PhD thesis, University of London.
64. Park JJ, Baum MJ (1999) Intracerebroventricular infusion of the galanin antagonist M40 attenuates heterosexual partner preference in ferrets. Behav Neurosci 113: 391-400.
65. Rudd JA, Ngan MP, Wai MK, King AG, Witherington J, Andrews PLR, Sanger GJ (2006) Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 392: 79-83.
66. Sanger GJ, Holbrook JD, Andrews PL (2011) The translational value of rodent gastrointestinal functions: a cautionary tale. Trends Pharmacol Sci 32: 402-409.
67. Horn CC, Kimball BA, Wang H, Kaus J, Dienel S, Nagy A, Gathright GR, Yates BJ, Andews PLR (2013) Why can't rodents vomit? A comparative behavioral, anatomical, and physiological study. PloS ONE 8(4): e60537.
68. Basso N, Passaro E, Jr. (1972) Effect of calcium on pentagastrin-, histamine-, bethanecol-, and insulinstimulated gastric secretion in the ferret. J Surg Res 13: 32-38.
69. Basso N, Umeda N, Roth JL, Passaro E, Jr., Pfeiffer CJ (1971) Effect of unilateral vagotomy on gastric secretion in the ferret. Gastroenterology 61: 207-212.
70. Pfeiffer CJ, Peters CM (1969) Gastric secretion in the chronic fistula ferret. Gastroenterology 57: 518-524.
71. Andrews PL, Grundy D, Lawes IN (1980) The role of the vagus and splanchnic nerves in the regulation of intragastric pressure in the ferret. J Physiol 307: 401-411.
72. Andrews PL, Grundy D, Scratcherd T (1980) Reflex excitation of antral motility induced by gastric distension in the ferret. J Physiol 298: 79-84.
73. Andrews PL, Scratcherd T (1980) The gastric motility patterns induced by direct and reflex excitation of the vagus nerves in the anaesthetized ferret. J Physiol 302: 363-378.
74. Andrews PLR (1979) PhD thesis: The vagal control of the gastro-intestinal tract. University of Sheffield.
75. Deshmukh DR, Shope TC (1983) Arginine requirement and ammonia toxicity in ferrets. J Nutr 113: 1664-1667.
76. Fitzakerley JL, Lucier GE (1988) Connections of a vagal communicating branch in the ferret. I. Pathways and cell body location. Brain Res Bull 20: 189-196.
77. Knox AP, Strominger NL, Battles AH, Carpenter DO (1993) Behavioral studies of emetic sensitivity in the ferret. Brain Res Bull 31: 477-484.
78. Strominger NL, Knox AP, Carpenter DO (1994) The connectivity of the area postrema in the ferret. Brain Res Bull 33: 33-47.
79. Boissonade FM, Davison JS, Egizii R, Lucier GE, Sharkey KA (1996) The dorsal vagal complex of the ferret: anatomical and immunohistochemical studies. Neurogastroenterol Motil 8: 255-272.
80. Zaman S, Woods AJ, Watson JW, Reynolds DJ, Andrews PLR (2000) The effect of the NK1 receptor antagonist CP-99,994 on emesis and c-fos protein induction by loperamide in the ferret. Neuropharmacology 39: 316-323.
81. Boissonade FM, Davison JS (1996) Effect of vagal and splanchnic nerve section on Fos expression in ferret brain stem after emetic stimuli. Am J Physiol 271: R228-236.
82. Boissonade FM, Sharkey KA, Davison JS (1994) Fos expression in ferret dorsal vagal complex after peripheral emetic stimuli. Am J Physiol 266: R1118-1126.
83. Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, Sharkey KA (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121: 767-774.
84. Sharkey KA, Cristino L, Oland LD, Van Sickle MD, Starowicz K, Pittman QJ, Guglielmotti V, Davison JS, Di Marzo V (2007) Arvanil, anandamide and Narachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 25: 2773-2782.
85. Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, Andrews PLR (1995) The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 115: 84-94.
86. Ariumi H, Saito R, Nago S, Hyakusoku M, Takano Y, Kamiya H (2000) The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis. Neurosci Lett 286: 123-126.
87. Leslie RA, Reynolds DJ, Andrews PL, Grahame-Smith DG, Davis CJ, Harvey JM (1990) Evidence for presynaptic 5-hydroxytryptamine3 recognition sites on vagal afferent terminals in the brainstem of the ferret. Neuroscience 38: 667-673.
88. Reynolds DJ, Lowenstein PR, Moorman JM, Grahame-Smith DG, Leslie RA (1994) Evidence for cholinergic vagal afferents and vagal presynaptic M1 receptors in the ferret. Neurochem Int 25: 455-464.
89. Billig I, Yates BJ, Rinaman L (2001) Plasma hormone levels and central c-Fos expression in ferrets after systemic administration of cholecystokinin. Am J Physiol Regul Integr Comp Physiol 281: R1243-R1255.
90. Saito R, Suehiro Y, Ariumi H, Migita K, Hori N, Hashiguchi T, Sakai M, Saeki M, Takano Y, Kamiya H (1998) Anti-emetic effects of a novel NK-1 receptor antagonist HSP-117 in ferrets. Neurosci Lett 254: 169-172.
91. Strominger NL, Brady R, Gullikson G, Carpenter DO (2001) Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation. Brain Res Bull 55: 445-451.
92. Ireland SJ, Tyers MB (1987) Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br J Pharmacol 90: 229-238.
93. Newberry NR, Watkins CJ, Reynolds DJ, Leslie RA, Grahame-Smith DG (1992) Pharmacology of the 5-hydroxytryptamine-induced depolarization of the ferret vagus nerve in vitro. Eur J Pharmacol 221: 157-160.
94. Kan KK, Jones RL, Ngan MP, Rudd JA (2004) Excitatory action of prostanoids on the ferret isolated vagus nerve preparation. Eur J Pharmacol 491: 37-41.
95. Blackshaw LA, Grundy D (1993) Effects of 5-hydroxytryptamine (5-HT) on the discharge of vagal mechanoreceptors and motility in the upper gastrointestinal tract of the ferret. J Auton Nerv Syst 45: 51-59.
96. Blackshaw LA, Grundy D (1993) Effects of 5-hydroxytryptamine on discharge of vagal mucosal afferent fibres from the upper gastrointestinal tract of the ferret. J Auton Nerv Syst 45: 41-50.
97. Page AJ, Blackshaw LA (1999) GABA(B) receptors inhibit mechanosensitivity of primary afferent endings. J Neurosci 19: 8597-8602.
98. Young RL, Page AJ, O'Donnell TA, Cooper NJ, Blackshaw LA (2007) Peripheral versus central modulation of gastric vagal pathways by metabotropic glutamate receptor 5. Am J Physiol Gastrointest Liver Physiol 292: G501-G511.
99. Endo T, Nemoto M, Minami M, Yoshioka M, Saito H, Parvez SH (1995) Changes in the afferent abdominal vagal nerve activity induced by cisplatin and copper sulfate in the ferret. Biog Amines 11: 399-407.
100. Minami M, Endo T, Yokota H, Ogawa T, Nemoto M, Hamaue N, Hirafuji M, Yoshioka M, Nagahisa A, Andrews PLR (2001) Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors. Eur J Pharmacol 428: 215-220.
101. Page AJ, Slattery JA, Milte C, Laker R, O'Donnell T, Dorian C, Brierley SM, Blackshaw LA (2007) Ghrelin selectively reduces mechanosensitivity of upper gastrointestinal vagal afferents. Am J Physiol Gastrointest Liver Physiol 292: G1376-G1384.
102. Young RL, Page AJ, Cooper NJ, Frisby CL, Blackshaw LA (2010) Sensory and motor innervation of the crural diaphragm by the vagus nerves. Gastroenterology 138: 1091-1101., e1-5.
103. Niedringhaus M, Jackson PG, Pearson R, Shi M, Dretchen K, Gillis RA, Sahibzada N (2008) Brainstem sites controlling the lower esophageal sphincter and crural diaphragm in the ferret: a neuroanatomical study. Auton Neurosci 144: 50-60.
104. Shintani T, Mori RL, Yates BJ (2003) Locations of neurons with respiratory-related activity in the ferret brainstem. Brain Res 974: 236-242.
105. Blackshaw LA, Staunton E, Lehmann A, Dent J (1999) Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol 277: G867-G874.
106. Partosoedarso ER, Abrahams TP, Scullion RT, Moerschbaecher JM, Hornby PJ (2003) Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 550: 149-158.
107. Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003) Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285: G566-G576.
108. Sanger GJ, Andrews PLR (2006) Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci 129: 3-16.
109. Richards CA, Andrews PL, Spitz L, Milla PJ (1998) Nissen fundoplication may induce gastric myoelectrical disturbance in children. J Pediatr Surg 33: 1801-1805.
110. Richards CA, Carr D, Spitz L, Milla PJ, Andrews PL (2000) Nissen-type fundoplication and its effects on the emetic reflex and gastric motility in the ferret. Neurogastroenterol Motil 12: 65-74.
111. Richards CA, Smith VV, Milla PJ, Spitz L, Andrews PL (2003) The histological appearances of Nissen-type fundoplication in the ferret. Neurogastroenterol Motil 15: 121-128.
112. Andrews PLR, Bhandari P, Davey PT, Bingham S, Marr HE, Blower PR (1992) Are all 5-HT3 receptor antagonists the same? Eur J Cancer 28A(Suppl. 1): S2-S6.
113. Borison HL (1989) Area postrema: chemoreceptor circumventricular organ of the medulla oblongata. Prog Neurobiol 32: 351-390.
114. Lang IM (1990) Digestive tract motor correlates of vomiting and nausea. Can J Physiol Pharmacol 68: 242-253.
115. Andrews PLR, Bingham S (1990) Adaptation of the mechanisms controlling gastric motility following chronic vagotomy in the ferret. Exp Physiol 75: 811-825.
116. Andrews PLR, Wood KL (1988) Vagally mediated gastric motor and emetic reflexes evoked by stimulation of the antral mucosa in anaesthetized ferrets. J Physiol 395: 1-16.
117. Percie du Sert N, Chu KM, Wai MK, Rudd JA, Andrews PL (2009) Reduced normogastric electrical activity associated with emesis: a telemetric study in ferrets. World J Gastroenterol 15: 6034-6043.
118. Goineau S, Rompion S, Guillaume P, Barrais L, Castagne V (2013) Using telemetry to automate detection of emesis in the ferret: new vistas for delayed emesis assessment. J Pharmacol Toxicol Meth 68: 160-165.
119. Andrews PLR, Torii Y, Saito H, Matsuki N (1996) The pharmacology of the emetic response to upper gastrointestinal tract stimulation in Suncus murinus. Eur J Pharmacol 307: 305-313.
120. Andrews PLR, Bhandari P, Garland S, Bingham S, Davis CJ, Hawthorn J, Davidson HIM, Roylance R, Lane S (1990) Does retching have a function?: an experimental study in the ferret. Pharmacodyn Ther (Life Sci Adv) 9: 135-152.
121. Percie du Sert N, Ho WS, Rudd JA, Andrews PLR (2010) Cannabinoid-induced reduction in antral pacemaker frequency: a telemetric study in the ferret. Neurogastroenterol Motil 22: 1257-1266., e324.
122. Davis CJ, Harding RK, Leslie RA, Andrews PLR (1986) The organisation of vomiting as a protective reflex. In: Davis CJ, Lake-Bakaar GV, Grahame-Smith DG, eds. Nausea and vomiting: mechanisms and treatment. Berlin: Springer-Verlag, pp. 65-75.
123. Makale MT, King GL (1992) Surgical and pharmacological dissociation of cardiovascular and emetic responses to intragastric CuSO4. Am J Physiol 263: R284-R291.
124. Horn CC, Richardson EJ, Andrews PLR, Friedman MI (2004) Differential effects on gastrointestinal and hepatic vagal afferent fibers in the rat by the anti-cancer agent cisplatin. Auton Neurosci 115: 74-81.
125. 3 receptor antagonists. In: Fozard JR, ed. The peripheral actions of 5-hydroxytryptamine. Oxford, UK: Oxford Medical Publications, pp. 354-376.
126. Andrews PLR, Rudd JA (2004) The role of tachykinins and the tachykinin NK1 receptor in nausea and emesis. In: Holzer P, ed. Handbook of experimental pharmacology. Berlin: Springer Verlag, pp. 359-440.
127. Onishi T, Mori T, Yanagihara M, Furukawa N, Fukuda H (2007) Similarities of the neuronal circuit for the induction of fictive vomiting between ferrets and dogs. Auton Neurosci 136: 20-30.
128. Whitwam JG, Morgan M, Owen JR, Goolden AW, Spiers AS, Goldman JM, Gordon-Smith EC (1978) General anaesthesia for high-dose total-body irradiation. Lancet 1: 128-129.
129. Tuor UI, Kondysar MH, Harding RK (1988) Emesis, radiation exposure, and local cerebral blood flow in the ferret. Radiat Res 114: 537-549.
130. Andrews PLR, Hawthorn J, Sanger GJ (1987) The effect of abdominal visceral nerve lesions and a novel 5HT-M receptor antagonist on cytotoxic and radiation induced emesis in the ferret. J Physiol 382: 47P.
131. Bermudez J, Boyle EA, Miner WD, Sanger GJ (1988) The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 58: 644-650.
132. Sagrada A, Turconi M, Bonali P, Schiantarelli P, Micheletti R, Montagna E, Nicola M, Algate DR, Rimoldi EM, Donetti A (1991) Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation. Cancer Chemother Pharmacol 28: 470-474.
133. Marr HE, Davey PT, Boyle EA, Blower PR (1994) Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret. Pharmacology 48: 283-292.
134. Andrews PLR, Bhandari P (1993) Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 32: 799-806.
135. Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, Twissell DJ, Ward P (1996) GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept 65: 45-53.
136. King GL, Landauer MR (1990) Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret. J Pharmacol Exp Ther 253: 1026-1033.
137. Sanazari JK, Wan XS, Krigsfeld GS, King GL, Miller A, Mick R, Gridley DS, Wroe AJ, Rightnar S, Dolney D, Kennedy AR (2013) Effects of solar particle event proton radiation on parameters related to ferret emesis. Radiat Res 180: 166-176.
138. 3 receptors antagonists and radiation-induced emesis: pre-clinical data. In: Reynolds DJ, Andrews PLR, Davis CJ, eds. Serotonin and the scientific basis of anti-emetic therapy. Oxford: Oxford Clinical Communications, pp. 50-59.
139. Zhang F, Wang L, Yang ZH, Liu ZT, Yue W (2006) Value of mink vomit model in study of anti-emetic drugs. World J Gastroenterol 12: 1300-1302.
140. Horn CC, Meyers K, Pak D, Nagy A, Apfel CC, Williams BA (2012) Post-anesthesia vomiting: impact of isoflurane and morphine on ferrets and musk shrews. Physiol Behav 106: 562-568.
141. Percie du Sert N, Holmes AM, Wallis R, Andrews PL (2012) Predicting the emetic liability of novel chemical entities: a comparative study. Br J Pharmacol 165: 1848-1867.
142. Percie du Sert N, Rudd JA, Apfel CC, Andrews PL (2011) Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT(3) receptor antagonists. Cancer Chemother Pharmacol 73: 667-686.
143. Barnes NM, Bunce KT, Naylor RJ, Rudd JA (1991) The actions of fentanyl to inhibit drug-induced emesis. Neuropharmacology 30: 1073-1083.
144. Torigoe K, Nakahara K, Rahmadi M, Yoshizawa K, Horiuchi H, Hirayama S, Imai S, Kuzumaki N, Otoh T, Yamashita A, Shakunga K, Nagase H, Matoba M, Suzuki T, Narita M (2012) Usefulness of olanzapine as an adjunct to opiod treatment and for the treatment of neuropathic pain. Anesthesiology 116: 159-169.
145. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, Cox BF, Brioni JD, Moreland RB (2005) Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav 81: 211-219.
146. Bountra C, Bunce K, Dale T, Gardner C, Jordan C, Twissell D, Ward P (1993) Anti-emetic profile of a nonpeptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 249: R3-R4.
147. Rudd JA, Naylor RJ (1994) Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology 33: 1607-1608.
148. Milano S, Blower P, Romain D, Grelot L (1995) The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis. J Pharmacol Exp Ther 274: 951-961.
149. Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17: 20-28.
150. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3: 1379-1384.
151. Rudd JA, Naylor RJ (1996) An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol 118: 209-214.
152. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Hesketh PJ (1993) Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer 29A(Suppl. 1): S35-S38.
153. Kubota Y, Mihara K, Ishii F, Ohno K, Ogata H, Makimura M, Kikuchi N, Kitano T (2004) [Effectiveness of anti-emetics for the prophylaxis of cisplatininduced delayed emesis: a systematic review]. Yakugaku Zasshi 124: 1-11.
154. Hesketh PJ (2005) Management of nausea and vomiting in cancer and cancer treatment. Sudbury, MA: Jones and Barlett Publishers, Inc.
155. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39: 1074-1080.
156. Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, Hale JJ, Mills SG, Finke PE, MacCoss M, Sadowski S, Ber E, Cascieri M, Hill RG, Macintyre DE, Hargreaves RJ (2000) The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39: 652-663.
157. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24: 2932-2947.
158. Dando TM, Perry CM (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64: 777-794.
159. Bateman N, Kerr S (2006) Gastrointestinal disorders. In: Lee A, ed. Adverse drug reactions, 2nd ed. London: Pharmaceutical Press, pp. 157-192.
160. Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PLR (2009) Opportunities for the replacement of animals in the study of nausea and vomiting. Br J Pharmacol 157: 865-880.
161. Davison JS, Oland LD, Andrews PLR (2003) Endogenous cholecystokinin activates CCK1 receptors to induce emesis in the ferret. Auton Neurosci 106: 43.
162. Hursti TJ, Avall-Lundqvist E, Borjeson S, Fredrikson M, Furst CJ, Steineck G, Peterson C (1996) Impact of tumour burden on chemotherapy-induced nausea and vomiting. Br J Cancer 74: 1114-1119.
163. Kim MS, Chey WD, Owyang C, Hasler WL (1997) Role of plasma vasopressin as a mediator of nausea and gastric slow wave dysrhythmias in motion sickness. Am J Physiol 272: G853-G862.
164. Thomford NR, Sirinek KR (1975) Intravenous vasopressin in patients with portal hypertension: advantages of continuous infusion. J Surg Res 18: 113-117.
165. Carpenter DO, Briggs DB, Strominger N (1984) Peptide-induced emesis in dogs. Behav Brain Res 11: 277-281.
166. Kim J, Napadow V, Kuo B, Barbieri R (2011) A combined HRV-fMRI approach to assess cortical control of cardiovagal modulation by motion sickness. Conf Proc IEEE Eng Med Biol Soc 2011: 2825-2828.
167. Furness JB (2006) The enteric nervous system. Malden, MA: Blackwell Publishing.
168. Stern RM, Koch KL, Leibowitz HW, Lindblad IM, Shupert CL, Stewart WR (1985) Tachygastria and motion sickness. Aviat Space Environ Med 56: 1074-1077.
169. Muth ER, Elkins AN (2007) High dose ondansetron for reducing motion sickness in highly susceptible subjects. Aviat Space Environ Med 78: 686-692.
170. Levine ME, Gillis MG, Koch SY, Voss AC, Stern RM, Koch KL (2008) Protein and ginger for the treatment of chemotherapy-induced delayed nausea. J Altern Complement Med 14: 545-551.
171. Koch KL (1997) A noxious trio: nausea, gastric dysrhythmias and vasopressin. Neurogastroenterol Motil 9: 141-142.
172. Koch KL, Stern RM, Vasey M, Botti JJ, Creasy GW, Dwyer A (1990) Gastric dysrhythmias and nausea of pregnancy. Dig Dis Sci 35: 961-968.
173. Cucchiara S, Minella R, Riezzo G, Vallone G, Vallone P, Castellone F, Auricchio S (1992) Reversal of gastric electrical dysrhythmias by cisapride in children with functional dyspepsia. Report of three cases. Dig Dis Sci 37: 1136-1140.
174. Geldof H, Van der Schee EJ, Smout AJ, Van de Merwe JP, Van Blankenstein M, Grashuis JL (1989) Myoelectrical activity of the stomach in gastric ulcer patients: an electrographic study. J Gastrointest Mot 1: 122-130.
175. Ogawa A, Mizuta I, Fukunaga T, Takeuchi N, Honaga E, Sugita Y, Mikami A, Inoue Y, Takeda M (2004) Electrogastrography abnormality in eating disorders. Psychiatry Clin Neurosci 58: 300-310.
176. Roche M, Bueno L, Vagne M, Blourde C (1982) Patterns of electrical activity in the digestive tract of the conscious cat. Br J Nutr 48: 129-135.
177. Fioramonti J, Bueno L (1980) Gastrointestinal myoelectric activity disturbances in gastric ulcer disease in rats and dogs. Dig Dis Sci 25: 575-580.
178. Ueno T, Chen JD (2004) Vomiting and gastric electrical dysrhythmia in dogs. Scand J Gastroenterol 39: 344-352.
179. Percie du Sert N, Chu KM, Wai MK, Rudd JA, Andrews PL (2010) Telemetry in a motion-sickness model implicates the abdominal vagus in motion-induced gastric dysrhythmia. Exp Physiol 95: 768-773.
180. LaCount LT, Barbieri R, Park K, Kim J, Brown EN, Kuo B, Napadow V (2011) Static and dynamic autonomic response with increasing nausea perception. Aviat Space Environ Med 82: 424-433.
181. Chen J, Song GQ, Yin J, Koothan T, Chen JD (2008) Electroacupuncture improves impaired gastric motility and slow waves induced by rectal distension in dogs. Am J Physiol Gastrointest Liver Physiol 295: G614-G620.
182. Wang ZS, Chen JDZ (2000) Robust ECG R-R wave detection using evolutionary-programming-based fuzzy inference system (EPFIS), and application to assessing brain-gut interaction. IEE Proc Sci Meas Technol 147: 351-356.
183. Imai K, Ariga H, Chen C, Mantyh C, Pappas TN, Takahashi T (2008) Effects of electroacupuncture on gastric motility and heart rate variability in conscious rats. Auton Neurosci 138: 91-98.
184. Fisher RD, Rentschler RE, Nelson JC, Godfrey TE, Wilbur DW (1982) Elevation of plasma antidiuretic hormones (ADH) associated with chemotherapy-induced emesis in man. Cancer Treat Rep 66: 25-29.
185. Rowe JW, Shelton RL, Helderman JH, Vestal RE, Robertson GL (1979) Influence of the emetic reflex on vasopressin release in man. Kidney Int 16: 729-735.
186. Page SR, Peterson DB, Crosby SR, Ang VT, White A, Jenkins JS, Nussey SS (1990) The responses of arginine vasopressin and adrenocorticotrophin to nausea induced by ipecacuanha. Clin Endocrinol (Oxf) 33: 761-770.
187. Koch KL, Summy-Long J, Bingaman S, Sperry N, Stern RM (1990) Vasopressin and oxytocin responses to illusory self-motion and nausea in man. J Clin Endocrinol Metab 71: 1269-1275.
188. Wilkens EP, Yates BJ (2005) Pretreatment with ondansetron blunts plasma vasopressin increases associated with morphine administration in ferrets. Anesth Analg 101: 1029-1033., table of contents.
189. Hawthorn J, Andrews PLR, Ang VT, Jenkins JS (1988) Differential release of vasopressin and oxytocin in response to abdominal vagal afferent stimulation or apomorphine in the ferret. Brain Res 438: 193-198.
190. Takeda N, Hasegawa S, Morita M, Horii A, Uno A, Yamatodani A, Matsunaga T (1995) Neuropharmacological mechanisms of emesis. II. Effects of antiemetic drugs on cisplatin-induced pica in rats. Methods Find Exp Clin Pharmacol 17: 647-652.
191. Parker LA (2003) Taste avoidance and taste aversion: evidence for two different processes. Learn Behav 31: 165-172.
192. Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, Lutz B, Zimmer A, Parker LA, Makriyannis A, Sharkey KA (2010) A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 161: 629-642.
193. Parker LA, Kwiatkowska M, Mechoulam R (2006) Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 87: 66-71.
194. Suri KB, Crampton GH, Daunton NG (1979) Motion sickness in cats: a symptom rating scale used in laboratory and flight tests. Aviat Space Environ Med 50: 614-618.
195. Chen JD, Qian L, Ouyang H, Yin J (2003) Gastric electrical stimulation with short pulses reduces vomiting but not dysrhythmias in dogs. Gastroenterology 124: 401-409.
196. King AG, Sanger GJ (2005) Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret. Neurosci Lett 376: 5-8.
197. Hawthorn J, Cunningham D (1990) Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br J Cancer 61: 56-60.
198. Gonsalves S, Watson J, Ashton C (1996) Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets. Eur J Pharmacol 305: 181-185.
199. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC (2001) PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40: 262-269.
200. Lau AH, Kan KK, Lai HW, Ngan MP, Rudd JA, Wai MK, Yew DT (2005) Action of ondansetron and CP-99,994 to modify behavior and antagonize cisplatininduced emesis in the ferret. Eur J Pharmacol 506: 241-247.
201. Osinski MA, Seifert TR, Shaughnessy TK, Gintant GA, Cox BF (2003) Emetic liability testing in ferrets. In: Enna SJ, Williams M, Ferkany JW, Kenakin T, Porsolt RD, Sullivan JP, eds. Current protocols in pharmacology. New York: John Willey & Sons, pp. 5.31.1-5.31.8.
202. Montana JG, Cooper N, Dyke HJ, Gowers L, Gregory JP, Hellewell PG, Miotla J, Morris K, Naylor R, Tuladhar B, Warneck JB (1998) PDE4 inhibitors: new xanthine analogues. Bioorg Med Chem Lett 8: 2925-2930.
203. Hesketh PJ, Grunberg SM, Herrstedt J, De Wit R, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ (2006) Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14: 354-360.
204. Sam TS, Chan SW, Rudd JA, Yeung JH (2001) Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret. Eur J Pharmacol 417: 231-237.
205. McCarthy LE, Borison HL (1983) Animal models for predicting antiemetic drug activity. In: Lazlo J, ed. Antiemetics and cancer chemotherapy. Baltimore, MD: Williams and Williams, pp. 21-33.
206. Endo T, Minami M, Hirafuji M, Ogawa T, Akita K, Nemoto M, Saito H, Yoshioka M, Parvez SH (2000) Neurochemistry and neuropharmacology of emesis - the role of serotonin. Toxicology 153: 189-201.
207. Yoshikawa T, Yoshida N, Oka M (2001) The broadspectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist. Br J Pharmacol 133: 253-260.
208. European Medicines Agency (2006) Guideline on nonclinical and clinical development of medicinal products for the treatment of nausea and vomiting associated with cancer chemotherapy. CPMP/EWP/4937/03. In EMEA ed. London, UK.
209. Plant M, Lloyd M (2010) The ferret. In: Hubrecht R, Kirkwood J, eds. The UFAW handbook on the care and management of laboratory and other research animals, 8th ed. Oxford: Wiley-Blackwell, pp. 418-432.
210. Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D, Hutton J, Altman DG (2009) Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS ONE 4: e7824.
211. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8: e1000412.
212. Lehmann A, Karrberg L (1996) Effects of N-methyl-Daspartate receptor antagonists on cisplatin-induced emesis in the ferret. Neuropharmacology 35: 475-481.
213. Hesketh PJ, Aapro M, Street JC, Carides AD (2009) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18: 1171-1177.
214. Apfel CC, Greim CA, Haubitz I, Goepfert C, Usadel J, Sefrin P, Roewer N (1998) A risk score to predict the probability of postoperative vomiting in adults. Acta Anaesthesiol Scand 42: 495-501.
215. Navari RM (2009) Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother 10: 629-644.
216. Percie du Sert N (2009) PhD thesis: An investigation into the mechanism of cisplatin-induced emesis. London, St George's University of London.
217. Potgieter FJ, Wilke PI, Van Jaarsveld H, Alberts DW (1996) The in vivo effect of different bedding materials on the antioxidant levels of rat heart, lung and liver tissue. J S Afr Vet Assoc 67: 27-30.
218. Gupta YK, Sharma SS (1996) Antiemetic activity of antioxidants against cisplatin-induced emesis in dogs. Environ Toxicol Pharmacol 1: 179-184.
219. Pugsley MK, Towart R, Authier S, Gallacher DJ, Curtis MJ (2010) Non-clinical models: validation, study design and statistical consideration in safety pharmacology. J Pharmacol Toxicol Methods 62: 1-3.
220. Seymour MT The pharmacokinetics and pharmacodynamics of chemotherapeutics agents. In: Andrews PLR, Sanger GJ, editors. Emesis in Anti-Cancer Therapy. London: Chapman & Hall; 1993. pp. 9-45.
221. Schelling G, Hauer D, Azad SC, Schmoelz M, Chouker A, Schmidt M, Hornuss C, Rippberger M, Briegel J, Thiel M, Vogeser M (2006) Effects of general anesthesia on anandamide blood levels in humans. Anesthesiology 104: 273-277.
222. Pyle NJ (1940) The use of ferrets in laboratory and research investigations. Am J Public Health Nations Health 30: 787-796.
223. Andrews PLR, Grundy D, Scratcherd T (1980) Vagal afferent discharge from mechanoreceptors in different regions of the ferret stomach. J Physiol 298: 513-524.
224. Hargreaves R (2002) Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 63 Suppl 11: 18-24.
225. Davey VA, Biederman GB (1998) Conditioned antisickness: indirect evidence from rats and direct evidence from ferrets that conditioning alleviates drug-induced nausea and emesis. J Exp Psychol Anim Behav Process 24: 483-491.
226. Rabin BM, Hunt WA (1992) Relationship between vomiting and taste aversion learning in the ferret: studies with ionizing radiation, lithium chloride, and amphetamine. Behav Neural Biol 58: 83-93.
227. Chu KM, Ngan MP, Wai MK, Yeung CK, Andrews PL, Percie du Sert N, Lin G, Rudd JA (2010) Olvanil, a non-pungent vanilloid enhances the gastrointestinal toxicity of cisplatin in the ferret. Toxicol Lett 192: 402-407.
228. Borison, HL, McCarthy, LE 1981. Physiologic basis of nausea and vomiting. pp. 33-39. In: Treatment of cancer chemotherapy-induced nausea and vomiting. Eds D.S. Poster, J.S. Penta, S. Bruno. Masson Publishing USA, Inc, NY.
229. Borison HL, Borison R, McCarthy LE (1981) Phylogenic and neurologic aspects of the vomiting process. J Clin Pharmacol 21: 23S-29S.
230. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl. 5): v232-v243.
231. Ng KS, Chua YC, Ban VF, Gresty M, Coen SJ, Sanger GJ, Williams SC, Barker G, Andrews P, Aziz Q (2011) Identifying human biomarkers of nausea for refining animal studies on emesis. Gastroenterology 140: S-368.
232. Bergstrom M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ogren M, Antoni G, Langstrom B, Eskola O, Scheinin M, Solin O, Majumdar AK, Constanzer ML, Battisti WP, Bradstreet TE, Gargano C, Hietala J (2004) Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 55: 1007-1012.
233. Borsook D, Upadhyay J, Klimas M, Schwarz AJ, Coimbra A, Baumgartner R, George E, Potter W, Large T, Bleakman D, Evelhoch J, Iyengar S, Becerra L, Hargreaves R (2012) Decision-making using fMRI in clinical drug development: revisiting the NK-1 receptor antagonist for pain. Drug Discov Today 17: 964-973.
234. Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG (1993) The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 250: R5-R6.
235. Cunningham D, Hawthorn J, Pople A, Gazet JC, Ford HT, Challoner T, Coombes RC (1987) Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet 1: 1461-1463.
236. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 340: 190-195.
237. Percie du Sert N, Rudd JA, Moss R, Andrews PL (2009) The delayed phase of cisplatin-induced emesis is mediated by the area postrema and not the abdominal visceral innervation in the ferret. Neurosci Lett 465: 16-20.
238. Andrews PL, Bhandari P(1993)The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Eur J Cancer 29A(Suppl. 1): S11-S16.
239. Gylys JA, Wright RN, Nicolosi WD, Buyniski JP, Crenshaw RR (1988) BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. J Pharmacol Exp Ther 244: 830-837.
240. Yoshida N, Omoya H, Kato S, Ito T (1992) 5-HT3 receptor antagonist effects of DAT-582, (R) enantiomer of AS-5370. Eur J Pharmacol 216: 435-440.
241. Fernandez AG, Puig J, Beleta J, Domenech T, Bou J, Berga P, Gristwood RW, Roberts DJ (1992) Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol 222: 257-264.
242. Fink-Jensen A, Judge ME, Hansen JB, Jacobsen P, Turski L, Olney J, Honore T (1992) Inhibition of cisplatin-induced emesis in ferrets by the non-NMDA receptor antagonists NBQX and CNQX. Neurosci Lett 137: 173-177.
243. Sancilio LF, Pinkus LM, Jackson CB, Munson HR, Jr. (1990) Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents. Eur J Pharmacol 181: 303-306.
244. del Rio J, Lasheras B, Berjon A, Romero G, Del Castillo J, Roca J, Monge A (1992) Novel 5-HT3 receptor antagonists. Quinoxaline derivatives with antiemetic activity in ferrets. Mechanisms and control of emesis. Montrouge: INSERM/John Libbey Eurotext, Ltd.
245. Kamato T, Miyata K, Ito H, Yuki H, Yamano M, Honda K (1991) Antiemetic effects of YM060, a potent and selective serotonin (5HT)3-receptor antagonist, in ferrets and dogs. Jpn J Pharmacol 57: 387-395.
246. Fukuda T, Setoguchi M, Inaba K, Shoji H, Tahara T (1991) The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol 196: 299-305.
247. Ji J, Bunnelle WH, Anderson DJ, Faltynek C, Dyhring T, Ahring PK, Rueter LE, Curzon P, Buckley MJ, Marsh KC, Kempf-Grote A, Meyer MD (2007) A-366833: a novelnicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: synthesis, analgesic efficacy and tolerability profile in animal models. Biochem Pharmacol 74: 1253-1262.
248. Nagakura Y, Kakimoto S, Matsuoka N (2007) Purinergic P2X receptor activation induces emetic responses in ferrets and Suncus murinus (house musk shrews). Br J Pharmacol 152: 464-470.
249. Kobayashi M, Kubo S, Iwata M, Ohtsu Y, Takahashi K, Shimizu Y (2011) ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity. Int Immunopharmacol 11: 732-739.
250. Montana JG, Buckley GM, Cooper N, Dyke HJ, Gowers L, Gregory JP, Hellewell PG, Kendall HJ, Lowe C, Maxey R, Miotla J, Naylor RJ, Runcie KA, Tuladhar B, Warneck JB (1998) Aryl sulfonamides as selective PDE4 inhibitors. Bioorg Med Chem Lett 8: 2635-2640.
251. Nakayama H, Yamakuni H, Higaki M, Ishikawa H, Imazumi K, Matsuo M, Mutoh S (2005) Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets. J Pharmacol Sci 98: 396-403.
252. Nakayama H, Yamakuni H, Nakayama A, Maeda Y, Imazumi K, Matsuo M, Mutoh S (2004) Diphenidol has no actual broad antiemetic activity in dogs and ferrets. J Pharmacol Sci 96: 301-306.
253. Ozaki A, Sukamoto T (1999) Improvement of cisplatininduced emesis and delayed gastric emptying by KB-R6933, a novel 5-HT3 receptor antagonist. Gen Pharmacol 33: 283-288.
254. Liu Q, Yang Q, Sun W, Vogel P, Heydorn W, Yu XQ, Hu Z, Yu W, Jonas B, Pineda R, Calderon-Gay V, Germann M, O'Neill E, Brommage R, Cullinan E, Platt K, Wilson A, Powell D, Sands A, Zambrowicz B, Shi ZC (2008) Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 325: 47-55.
255. Sam TS, Ngan MP, Riendeau D, Robichaud A, Rudd JA (2007) Action of cyclooxygenase inhibitors and a leukotriene biosynthesis inhibitor on cisplatin-induced acute and delayed emesis in the ferret. J Pharmacol Sci 103: 189-200.
256. Robichaud A, Tattersall FD, Choudhury I, Rodger IW (1999) Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 38: 289-297.
257. Watanabe Y, Asai H, Ishii T, Kiuchi S, Okamoto M, Taniguchi H, Nagasaki M, Saito A (2008) Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S, 3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1, 1'-biphenyl]-4-carbonitrile dihydrochloride, as a brainpenetrating antagonist of tachykinin NK1 receptor. J Pharmacol Sci 106: 121-127.
258. Leonard AK, Sileno AP, Brandt GC, Foerder CA, Quay SC, Costantino HR (2007) In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm 335: 138-146.
259. Showell GA, Barnes MJ, Daiss JO, Mills JS, Montana JG, Tacke R, Warneck JB (2006) (R)-sila-venlafaxine: a selective noradrenaline reuptake inhibitor for the treatment of emesis. Bioorg Med Chem Lett 16: 2555-2558.
260. Angel I, Schoemaker H, Prouteau M, Garreau M, Langer SZ (1993) Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol 232: 139-145.
261. Warneck JB, Cheng FH, Barnes MJ, Mills JS, Montana JG, Naylor RJ, Ngan MP, Wai MK, Daiss JO, Tacke R, Rudd JA (2008) Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret. Toxicol Appl Pharmacol 232: 369-375.
262. Hasegawa M, Sasaki T, Sadakane K, Tabuchi M, Takeda Y, Kimura M, Fujii Y (2002) Studies for the emetic mechanisms of ipecac syrup (TJN-119) and its active components in ferrets: involvement of 5-hydroxytryptamine receptors. Jpn J Pharmacol 89: 113-119.
263. Costall B, Domeney AM, Gunning SJ, Kelly ME, Naylor RJ, Nohria V, Owera-Atepo JB, Simpson KM, Tan CC, Tattersall D (1987) The action of dazopride to enhance gastric emptying and block emesis. Neuropharmacology 26: 669-677.
264. Duffy RA, Morgan C, Naylor R, Higgins GA, Varty GB, Lachowicz JE, Parker EM (2012). Rolapitant (SCH 619734): A potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Bichem Behav 102: 95-100.
265. Gardner CJ, Twissell DJ, Dale TJ, Gale JD, Jordan CC, Kilpatrick GJ, Bountra C, Ward P (1995) The broadspectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol 116: 3158-3163.
266. Shishido Y, Wakabayashi H, Koike H, Ueno N, Nukui S, Yamagishi T, Murata Y, Naganeo F, Mizutani M, Shimada K, Fujiwara Y, Sakakibara A, Suga O, Kusano R, Ueda S, Kanai Y, Tsuchiya M, Satake K (2008) Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist "CJ-17,493". Bioorg Med Chem 16: 7193-7205.
267. Tattersall FD, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod AM, Ladduwahetty T, Keown L, Swain C, Baker R, Cascieri M, Ber E, Metzger J, MacIntyre DE, Hill RG, Hargreaves RJ. (1996). Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology, 35: 1121-1129.
268. Price MT, Olney JE (1990) Excitatory amino acid antagonists as anti-emetics. Soc Neurosci Abstr 16: 377.
269. Rudd JA, Naylor RJ (1994) Modulation of emesis by 5HT1A receptors. Pathophysiology 1: 267-268.
270. Bhandari P, Andrews PLR (1991) Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret. Eur J Pharmacol 204: 273-280.
271. Sam TS, Kan KK, Ngan MP, Rudd JA, Yeung JH (2003) Action of metyrapone and tetracosactrin to modify cisplatin-induced acute and delayed emesis in the ferret. Eur J Pharmacol 466: 163-168.
272. Barnes, J.M., Barnes, N.M., Costall, B., Naylor, R.J., Tattersall, F.D. (1988). Reserpine, para-chlorophenylalanine and fenfluramine antagonise cisplatin-induced emesis in the ferret. Neuropharmacology, 27: 783-790.
273. Kim JH, Yoon IS, Lee BH, Choi SH, Lee JH, Lee JH, Jeong SM, Kim SC, Park CK, Lee SM, Nah SY (2005) Effects of Korean red ginseng extract on cisplatininduced nausea and vomiting. Arch Pharm Res 28: 680-684.
274. Suzuki T, Nurrochmad A, Ozaki M, Khotib J, Nakamura A, Imai S, Shibasaki M, Yajima Y, Narita M (2005) Effect of selective GABAB receptor agonist baclofen on the U-opiod receptor agonistinduced anti-nociceptive, emetic and rewarding effects. Neuropharmacology 49: 1121-1131.